Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

INDUSTRY 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 4Plasma cell 4Genitourinary 4Sarcoma 3Thoracic 2Lymphoid 2Other hematologic neoplasm 1Breast 1

Conditions

Kidney Neoplasms 3Neoplasms 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × perifosine × Genitourinary × Clear all
NCT00448721 2018-03-01

A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

AEterna Zentaris

Phase 2 Completed
24 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00498966 2018-02-05

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

AEterna Zentaris

Phase 2 Completed
50 enrolled
Genitourinary

Kidney Neoplasms

NCT00398814 2014-02-19

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

AEterna Zentaris

Phase 1 Completed
30 enrolled
GastrointestinalGenitourinary

Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT00399152 2014-02-19

Perifosine + Sunitinib Malate for Patients With Advanced Cancers

AEterna Zentaris

Phase 1 Completed
15 enrolled
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡